Freiburg im Breisgau, Germany – January 8, 2026 – Eleva, a pioneer in discovering and developing previously inaccessible biologics, today announced the appointment of Dr. Erich Rajkovic, MBA, as Chief Business Officer. Erich Rajkovic joined Eleva from Affimed, Mannheim/Germany, where he played a key role in originating, negotiating and closing several strategic partnerships with leading pharma and biotechnology companies, as well as academic institutions. At Eleva, he will lead the continued strategic expansion of the company's pipeline and partnering activities across proprietary programs and external collaborations, supporting the company's next phase of growth. "Erich's proven expertise in fostering innovation and building frameworks to drive partnered and proprietary development programs is a valuable addition to our organization. We look forward to continuing and accelerating our pipeline expansion efforts, under his leadership and with his deep experience across business development and R&D," added Björn Cochlovius, Ph.D., Chief Executive Officer of Eleva. "We also would like to thank Henrik Luessen for his contributions over the past two and ...Full story available on Benzinga.com